{"title":"达格列嗪显著延长CKD患者的生存期","authors":"Iskandar Idris","doi":"10.1002/doi2.00025","DOIUrl":null,"url":null,"abstract":"<p>Data from a recent renal outcomes trial presented at the ESC Congress showed dapagliflozin significantly prolongs survival in patients with chronic kidney disease with and without type-2 diabetes.</p>","PeriodicalId":100370,"journal":{"name":"Diabetes, Obesity and Metabolism Now","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/doi2.00025","citationCount":"0","resultStr":"{\"title\":\"Dapagliflozin significantly prolongs survival in CKD patients\",\"authors\":\"Iskandar Idris\",\"doi\":\"10.1002/doi2.00025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Data from a recent renal outcomes trial presented at the ESC Congress showed dapagliflozin significantly prolongs survival in patients with chronic kidney disease with and without type-2 diabetes.</p>\",\"PeriodicalId\":100370,\"journal\":{\"name\":\"Diabetes, Obesity and Metabolism Now\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/doi2.00025\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity and Metabolism Now\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/doi2.00025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity and Metabolism Now","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/doi2.00025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dapagliflozin significantly prolongs survival in CKD patients
Data from a recent renal outcomes trial presented at the ESC Congress showed dapagliflozin significantly prolongs survival in patients with chronic kidney disease with and without type-2 diabetes.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
